Regional Chemotherapy of the Liver for Colorectal Malignancies

1988 ◽  
pp. 168-174
Author(s):  
H. H. Gruenagel ◽  
E. Molzahn ◽  
U. Freund ◽  
D. Groß
Keyword(s):  
Regional Chemotherapy

Experiences with Regional Chemotherapy

1962 ◽  
Vol 85 (1) ◽  
pp. 84 ◽  
Author(s):  
JOHN S. STEHLIN
Keyword(s):  
Regional Chemotherapy

Implementation of hepatic artery infusion (HAI) chemotherapy for unresectable colorectal liver metastases (CRLM): The University of Miami experience.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 96-96
Author(s):  
Agustin Pimentel ◽  
Joshua Kronenfeld ◽  
Vikas Dudeja ◽  
Nipun B. Merchant ◽  
Lauren Nicole Gallegos ◽  
...  
Keyword(s):  
Systemic Chemotherapy ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Regional Chemotherapy ◽  
Complete Resection ◽  
Hepatic Artery Infusion ◽  
Braf Mutations ◽  
Perioperative Morbidity ◽  
Academic Center ◽  
Primary Colon

96 Background: In patients with unresectable liver-confined CRLM, regional chemotherapy via HAI in combination with modern systemic chemotherapy (CT) can achieve hepatic disease control and expand surgical resectability. We describe patient selection and early outcomes following implementation of a HAI program at our tertiary referral academic center. Methods: We analyzed demographics, previous systemic treatment, primary tumor location, molecular profiling, extent of hepatic/extrahepatic disease, perioperative HAI outcomes (toxicity, conversion to resection/ablation, radiographic response), and overall survival (OS) in CRLM patients selected for HAI treatment (01/2018—06/2020) after multidisciplinary review. Results: Of 35 patients with unresectable CRLM (primary: colon, n = 24; rectum, n = 11) selected for HAI, 57% were heavily pre-treated (with at least 2 lines of pre-HAI systemic chemotherapy), 71% had a Fong clinical risk score ≥3, 86% presented with synchronous disease, 80% had bilobar metastasis, and 86% had > 5 tumors. All tumors were microsatellite stable, with 20% harboring KRAS/NRAS mutations and none had class I/II BRAF mutations. HAI was initiated at a median 14 (IQR 3, 64) months after CRLM diagnosis, and administered for a median of 7 (range 2, 16) cycles; 91% of patients (31/34) received concurrent HAI and systemic chemotherapy. Although most (69%) patients experienced some degree of hepatic toxicity during HAI therapy resulting in FUDR dose reduction and steroid administration, biliary sclerosis requiring intervention was observed in only 3 (9%) of patients. The overall perioperative morbidity was 17%, and there were no surgical-related 90-day mortalities following HAI pump placement. Excluding patients who initiated HAI treatment within the last 3 months of the study period (n = 3), 13 of 32 patients (41%) were rendered disease-free in the liver following complete resection and/or ablation in combination with HAI/systemic chemotherapy; in the remaining 19 patients (59%), hepatic progression-free survival was 7.3 months (IQR 4, 12). At a median follow-up of 11.2 months, post-HAI median OS for the overall cohort was 12.3 (IQR 7, 20) months. Patients undergoing complete resection/ablation demonstrated improved survival compared with those with progressive disease (median 20 vs 12 months, respectively). Conclusions: Implementation of a HAI program for multimodality liver-directed management of unresectable CRLM is feasible and is associated with meaningful clinical outcomes unlikely to be achieved with systemic therapy alone in heavily pre-treated patients.

Modulation of resistance to regional chemotherapy in the extremity melanoma model

Surgery ◽  
2004 ◽  
Vol 136 (2) ◽  
pp. 210-218 ◽  
Author(s):  
Elizabeth G. Grubbs ◽  
Tomio Ueno ◽  
Omar Abdel-Wahab ◽  
Tsung-Yen Cheng ◽  
Scott K. Pruitt ◽  
...  
Keyword(s):  
Regional Chemotherapy ◽  
Melanoma Model

scholarly journals Video-assisted transcatheter lung perfusion regional chemotherapy

2005 ◽  
Vol 27 (6) ◽  
pp. 1079-1082 ◽  
Author(s):  
M JINBO ◽  
K UEDA ◽  
Y KANEDA ◽  
M SUDO ◽  
T LI ◽  
...  
Keyword(s):  
Regional Chemotherapy ◽  
Lung Perfusion ◽  
Video Assisted

The Importance of Exposure Time in Regional Chemotherapy: Mitomycin C and Fluoropyrimidines1

1988 ◽  
pp. 43-48 ◽  
Author(s):  
E. A. de Bruijn ◽  
P. H. Th. J. Slee ◽  
P. J. K. Kuppen ◽  
R. M. van der Hoeven ◽  
U. R. Tjaden ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Exposure Time ◽  
Regional Chemotherapy

scholarly journals Multimodal Oncological Therapy Comprising Stents, Brachytherapy, and Regional Chemotherapy for Cholangiocarcinoma

Gut and Liver ◽  
2010 ◽  
Vol 4 (Suppl.1) ◽  
pp. S82 ◽  
Author(s):  
Tomáš Andrašina ◽  
Vlastimil Válek ◽  
Jiří Pánek ◽  
Zdeněk Kala ◽  
Igor Kiss ◽  
...  
Keyword(s):  
Regional Chemotherapy ◽  
Oncological Therapy

Results of Regional Chemotherapy Using the Aortic Stop-Flow Technique in Advanced Pancreatic Carcinoma

Surgery Today ◽  
2006 ◽  
Vol 36 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Frank Meyer ◽  
Thomas Gebauer ◽  
Reinhard Grote ◽  
Jens Martens-Lobenhoffer ◽  
Karsten Ridwelski ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Regional Chemotherapy ◽  
Advanced Pancreatic Carcinoma ◽  
Stop Flow

scholarly journals Preliminary study of an esterase-susceptible water-soluble agent (S-73) for regional chemotherapy

Cancer ◽  
1967 ◽  
Vol 20 (5) ◽  
pp. 826-828 ◽  
Author(s):  
Louis E. Goodman ◽  
Adolph Ulfohn ◽  
Stanley P. Kramer ◽  
Simon Calle ◽  
Daniel Bakal ◽  
...  
Keyword(s):  
Regional Chemotherapy ◽  
Water Soluble ◽  
Preliminary Study
Sign in / Sign up

Export Citation Format

Share Document